STOCK TITAN

Senseonics to Participate in the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.

Management is scheduled to present on Thursday, June 9, 2022 at 1:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Relations Contact:

Philip Taylor

Investor Relations

415-937-5406

Investors@senseonics.com

Source: Senseonics Holdings, Inc.

Senseonics Holdings Inc

NYSE:SENS

SENS Rankings

SENS Latest News

SENS Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Electronic Technology, Electronic Components, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Germantown

About SENS

senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm"​) system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.